SWOG clinical trial number
SWOG-9504

A Phase II Trial of Concurrent Cisplatin/VP-16 and Radiotherapy Followed by Consolidation Docetaxel (Taxotere®) in Stage III-B Non-Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Phase II Trial of Concurrent Cisplatin/VP-16 and Radiotherapy Followed by Consolidation Docetaxel (Taxotere®) in Stage III-B Non-Small Cell Lung Cancer
Activated
10/15/1996
Closed
12/01/1998

Research committees

Lung Cancer

Publication Information Expand/Collapse

2019

Clinical prognostic model for older patients with advanced non-small cell lung cancer

AK Ganti;X Wang;T Stinchcombe;Y Wang;J Bradley;HJ Cohen;K Kelly;R Paulus;SS Ramalingam;EE Vokes;H Pang Journal of Geriatric Oncology Feb 20. pii: S1879-4068(18)30197-8. doi: 10.1016/j.jgo.2019.02.007. [Epub ahead of print]

PMid: PMID30797707

2007

Patient demographics in HOG LUN 01-24 versus SWOG 9504: apples versus oranges [PMID17922970]

LE Gaspar Clinical Lung Cancer 8(9):478-482

2006

Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504)

DR Gandara;K Chansky;KS Albain;LE Gaspar;PN Lara Jr;K Kelly;K Crowley;RB Livingston Clinical Lung Cancer 8(2):116-121

2005

Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504)

DR Gandara;K Chansky;LE Gaspar;KS Albain;PN Lara;J Crowley Proc of the ASCO, JCO 23(16S):635s (#7059)

Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.

LE Gaspar;K Chansky;KS Albain;E Vallieres;V Rusch;JJ Crowley;RB Livingston;DR Gandara Journal of Clinical Oncology 23(13):2955-2961

Southwest Oncology Group: Two decades of experience in non-small cell lung cancer

AT Turrisi;J Crowley;K Albain;L Gaspar;D Gandara Seminars in Oncology 32(2Suppl3):S119-S121

PMid: PMID16015548

Therapeutic strategies for combined-modality therapy of locally advanced non-small cell lung cancer: rationale for consolidation docetaxel therapy

DR Gandara;E Vallieres;LE Gaspar;K Kelly;KS Albain;RS Herbst Jr;PN Lara Jr;P Mack;PH Gumerlock;JJ Crowley Clinical Lung Cancer 7 Suppl 3:S93-97

2003

Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group study S9504

DR Gandara;K Chansky;KS Albain;BR Leigh;LE Gaspar;PN Lara;H Burris;P Gumerlock;JP Kuebler;JD Bearden;J Crowley;R Livingston Journal of Clinical Oncology 21(10):2004-2010

2001

Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival

LE Gaspar;DR Gandara;K Chansky;KS Albain;PN Lara Jr;JJ Crowley;RB Livingston Proc of the American Society of Clinical Oncology 20:315a(#1255)

2000

Prolonged survival in pathologic stage IIIb non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel: a phase II study (S9504) of the Southwest Oncology Group (SWOG).

DR Gandara;LC Lovato; KS Albain;B Leigh;PN Lara;JJ Crowley;K Stelzer;RB Livingston Proc of the American Society of Clinical Oncology 19:490a(#1916)

Pathologic stage IIIb non-small cell lung cancer (NSCLC): prolonged survival with consolidation docetaxel following concurrent chemoradiotherapy (SWOG 9504).

DR Gandara;LC Lovato;KS Albain;B Leigh;PN Lara;JJ Crowley;RB Livingston Lung Cancer 29(Suppl.2):92(#302)

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007